S&P 500   4,294.51 (+0.34%)
DOW   33,930.60 (+0.50%)
QQQ   332.31 (+0.58%)
AAPL   173.26 (+0.67%)
MSFT   292.62 (+0.24%)
META   180.84 (+0.19%)
GOOGL   122.11 (+0.35%)
AMZN   142.72 (-0.58%)
TSLA   929.59 (+3.28%)
NVDA   188.15 (+0.57%)
NIO   21.37 (+1.23%)
BABA   94.13 (-0.68%)
AMD   100.84 (+0.01%)
MU   64.35 (-1.06%)
T   18.42 (+0.82%)
CGC   3.70 (+12.12%)
GE   79.76 (-0.21%)
F   16.34 (+0.99%)
DIS   125.04 (+2.85%)
AMC   23.76 (-2.78%)
PYPL   101.37 (+0.27%)
PFE   49.78 (-0.66%)
NFLX   250.38 (+0.43%)
S&P 500   4,294.51 (+0.34%)
DOW   33,930.60 (+0.50%)
QQQ   332.31 (+0.58%)
AAPL   173.26 (+0.67%)
MSFT   292.62 (+0.24%)
META   180.84 (+0.19%)
GOOGL   122.11 (+0.35%)
AMZN   142.72 (-0.58%)
TSLA   929.59 (+3.28%)
NVDA   188.15 (+0.57%)
NIO   21.37 (+1.23%)
BABA   94.13 (-0.68%)
AMD   100.84 (+0.01%)
MU   64.35 (-1.06%)
T   18.42 (+0.82%)
CGC   3.70 (+12.12%)
GE   79.76 (-0.21%)
F   16.34 (+0.99%)
DIS   125.04 (+2.85%)
AMC   23.76 (-2.78%)
PYPL   101.37 (+0.27%)
PFE   49.78 (-0.66%)
NFLX   250.38 (+0.43%)
S&P 500   4,294.51 (+0.34%)
DOW   33,930.60 (+0.50%)
QQQ   332.31 (+0.58%)
AAPL   173.26 (+0.67%)
MSFT   292.62 (+0.24%)
META   180.84 (+0.19%)
GOOGL   122.11 (+0.35%)
AMZN   142.72 (-0.58%)
TSLA   929.59 (+3.28%)
NVDA   188.15 (+0.57%)
NIO   21.37 (+1.23%)
BABA   94.13 (-0.68%)
AMD   100.84 (+0.01%)
MU   64.35 (-1.06%)
T   18.42 (+0.82%)
CGC   3.70 (+12.12%)
GE   79.76 (-0.21%)
F   16.34 (+0.99%)
DIS   125.04 (+2.85%)
AMC   23.76 (-2.78%)
PYPL   101.37 (+0.27%)
PFE   49.78 (-0.66%)
NFLX   250.38 (+0.43%)
S&P 500   4,294.51 (+0.34%)
DOW   33,930.60 (+0.50%)
QQQ   332.31 (+0.58%)
AAPL   173.26 (+0.67%)
MSFT   292.62 (+0.24%)
META   180.84 (+0.19%)
GOOGL   122.11 (+0.35%)
AMZN   142.72 (-0.58%)
TSLA   929.59 (+3.28%)
NVDA   188.15 (+0.57%)
NIO   21.37 (+1.23%)
BABA   94.13 (-0.68%)
AMD   100.84 (+0.01%)
MU   64.35 (-1.06%)
T   18.42 (+0.82%)
CGC   3.70 (+12.12%)
GE   79.76 (-0.21%)
F   16.34 (+0.99%)
DIS   125.04 (+2.85%)
AMC   23.76 (-2.78%)
PYPL   101.37 (+0.27%)
PFE   49.78 (-0.66%)
NFLX   250.38 (+0.43%)

Merck & Co., Inc. - MRK Stock Forecast, Price & News

$90.29
-0.73 (-0.80%)
(As of 08/15/2022 12:41 PM ET)
Add
Compare
Today's Range
$89.90
$90.98
50-Day Range
$84.50
$94.96
52-Week Range
$70.89
$95.72
Volume
254,290 shs
Average Volume
11.64 million shs
Market Capitalization
$228.73 billion
P/E Ratio
13.83
Dividend Yield
3.03%
Price Target
$97.44

Merck & Co., Inc. MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.61 Rating Score
Upside/​Downside
8.0% Upside
$97.44 Price Target
Short Interest
Healthy
0.66% of Shares Sold Short
Dividend Strength
Strong
Based on Four Factors
Sustainability
-2.29
Upright™ Environmental Score
News Sentiment
0.28mentions of Merck & Co., Inc. in the last 14 days
Based on 12 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
-1.64%
From $7.31 to $7.19 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.68 out of 5 stars

Medical Sector

99th out of 1,128 stocks

Pharmaceutical Preparations Industry

34th out of 554 stocks

MRK stock logo

About Merck & Co., Inc. (NYSE:MRK) Stock

Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; Ridgeback Biotherapeutics; and Gilead Sciences, Inc. to jointly develop and commercialize long-acting treatments in HIV. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.

Merck & Co., Inc. Trading Down 0.5 %

NYSE:MRK traded down $0.44 during mid-day trading on Monday, hitting $90.58. 34,208 shares of the company's stock were exchanged, compared to its average volume of 11,643,757. The company has a 50 day simple moving average of $90.09 and a 200-day simple moving average of $85.79. The firm has a market capitalization of $229.46 billion, a P/E ratio of 13.94, a PEG ratio of 1.23 and a beta of 0.32. The company has a current ratio of 1.39, a quick ratio of 1.15 and a debt-to-equity ratio of 0.66. Merck & Co., Inc. has a fifty-two week low of $70.89 and a fifty-two week high of $95.72.

Merck & Co., Inc. (NYSE:MRK - Get Rating) last posted its quarterly earnings data on Thursday, July 28th. The company reported $1.87 earnings per share for the quarter, topping the consensus estimate of $1.69 by $0.18. The company had revenue of $14.59 billion for the quarter, compared to analysts' expectations of $13.85 billion. Merck & Co., Inc. had a net margin of 29.00% and a return on equity of 48.45%. Merck & Co., Inc.'s revenue for the quarter was up 28.0% compared to the same quarter last year. During the same period in the prior year, the business earned $1.31 earnings per share. As a group, research analysts expect that Merck & Co., Inc. will post 7.31 earnings per share for the current year.

Merck & Co., Inc. Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, October 7th. Investors of record on Thursday, September 15th will be given a dividend of $0.69 per share. This represents a $2.76 annualized dividend and a yield of 3.05%. The ex-dividend date is Wednesday, September 14th. Merck & Co., Inc.'s dividend payout ratio is currently 42.27%.

Analyst Upgrades and Downgrades

Several research firms have recently commented on MRK. Daiwa Capital Markets raised Merck & Co., Inc. from a "neutral" rating to a "buy" rating and boosted their price target for the stock from $89.00 to $102.00 in a research report on Wednesday, July 6th. Atlantic Securities lifted their price objective on Merck & Co., Inc. from $105.00 to $110.00 and gave the company an "overweight" rating in a report on Wednesday, July 13th. Mizuho assumed coverage on Merck & Co., Inc. in a report on Friday, June 24th. They set a "buy" rating and a $100.00 price objective for the company. Morgan Stanley raised their price target on shares of Merck & Co., Inc. from $88.00 to $92.00 and gave the company an "equal weight" rating in a research note on Friday, July 29th. Finally, UBS Group lifted their target price on shares of Merck & Co., Inc. from $76.00 to $98.00 and gave the company a "neutral" rating in a research note on Monday, July 18th. Eight research analysts have rated the stock with a hold rating, nine have issued a buy rating and two have given a strong buy rating to the stock. According to MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $97.44.

Receive MRK Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Merck & Co., Inc. and its competitors with MarketBeat's FREE daily newsletter.

MRK Stock News Headlines

3 Pharma Stocks' Post-Earnings Price Moves (MRK)
The health care sector is participating in the S&P's nascent rally, but pharmaceuticals AbbVie, Merck and Pfizer are holding up well relative to the market.
Merck beats expectations, helped by Keytruda sales
Merck is posting second-quarter sales that easily topped Wall Street expectations, boosted by sales growth of some of its key drugs
Copper Exploration Heating Up
Canada is already known as a miner's paradise. But British Columbia (BC) is quietly becoming the new copper hotspot. That's because copper is critical to the world's shift to renewable energy. Biden earmarked $226 billion in new infrastructure projects all requiring copper.
Three Watchlist Stocks to Capitalize on Sector Rotation
Sector rotation is a common market event based on the theory that economies move in cycles. Here are three stocks, one apiece, from sectors that institutions are rotating into.
10 Famous Value Stocks that Underperformed in 2022
Elon Musk is Worried about China
China controls 80% of the lithium market and Tesla needs a lot of lithium for its cars. But a junior miner just discovered a once-in-a-lifetime deposit of this "white gold."
Is it a Good Choice to Invest in Merck & Co. (MRK)?
See More Headlines
Receive MRK Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Merck & Co., Inc. and its competitors with MarketBeat's FREE daily newsletter.

MRK Company Calendar

Ex-Dividend for 7/8 Dividend
6/14/2022
Dividend Payable
7/08/2022
Last Earnings
7/28/2022
Today
8/15/2022
Ex-Dividend for 10/7 Dividend
9/14/2022
Dividend Payable
10/07/2022
Next Earnings (Estimated)
10/27/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceuticals
Sector
Medical
CUSIP
58933Y10
Employees
68,000
Year Founded
1891

Price Target and Rating

Average Stock Price Forecast
$97.44
High Stock Price Forecast
$110.00
Low Stock Price Forecast
$85.00
Forecasted Upside/Downside
+7.9%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.61
Research Coverage
18 Analysts

Profitability

Net Income
$13.05 billion
Pretax Margin
32.40%

Debt

Sales & Book Value

Annual Sales
$48.70 billion
Cash Flow
$7.26 per share
Book Value
$15.14 per share

Miscellaneous

Outstanding Shares
2,533,280,000
Free Float
2,525,933,000
Market Cap
$228.73 billion
Optionable
Optionable
Beta
0.32

Social Links















MRK Stock - Frequently Asked Questions

Should I buy or sell Merck & Co., Inc. stock right now?

18 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Merck & Co., Inc. in the last twelve months. There are currently 8 hold ratings, 9 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" MRK shares.
View MRK analyst ratings
or view top-rated stocks.

What is Merck & Co., Inc.'s stock price forecast for 2022?

18 Wall Street analysts have issued 12-month price objectives for Merck & Co., Inc.'s stock. Their MRK share price forecasts range from $85.00 to $110.00. On average, they anticipate the company's stock price to reach $97.44 in the next twelve months. This suggests a possible upside of 7.1% from the stock's current price.
View analysts price targets for MRK
or view top-rated stocks among Wall Street analysts.

How have MRK shares performed in 2022?

Merck & Co., Inc.'s stock was trading at $76.64 at the beginning of 2022. Since then, MRK stock has increased by 18.8% and is now trading at $91.02.
View the best growth stocks for 2022 here
.

When is Merck & Co., Inc.'s next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, October 27th 2022.
View our MRK earnings forecast
.

How were Merck & Co., Inc.'s earnings last quarter?

Merck & Co., Inc. (NYSE:MRK) issued its earnings results on Thursday, July, 28th. The company reported $1.87 earnings per share for the quarter, beating the consensus estimate of $1.69 by $0.18. The firm earned $14.59 billion during the quarter, compared to the consensus estimate of $13.85 billion. Merck & Co., Inc. had a trailing twelve-month return on equity of 48.45% and a net margin of 29.00%. Merck & Co., Inc.'s revenue was up 28.0% on a year-over-year basis. During the same quarter last year, the company earned $1.31 EPS.

How often does Merck & Co., Inc. pay dividends? What is the dividend yield for Merck & Co., Inc.?

Merck & Co., Inc. declared a quarterly dividend on Tuesday, July 26th. Shareholders of record on Thursday, September 15th will be paid a dividend of $0.69 per share on Friday, October 7th. This represents a $2.76 annualized dividend and a yield of 3.03%. The ex-dividend date is Wednesday, September 14th.
Read our dividend analysis for MRK
.

Is Merck & Co., Inc. a good dividend stock?

Merck & Co., Inc. (NYSE:MRK) pays an annual dividend of $2.76 per share and currently has a dividend yield of 3.03%. The company has been increasing its dividend for 12 consecutive years, indicating the company has a strong committment to maintain and grow its dividend. The dividend payout ratio is 42.27%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, MRK will have a dividend payout ratio of 38.39% next year. This indicates that the company will be able to sustain or increase its dividend.
Read our dividend analysis for MRK.

What guidance has Merck & Co., Inc. issued on next quarter's earnings?

Merck & Co., Inc. updated its FY 2022 earnings guidance on Thursday, August, 4th. The company provided earnings per share (EPS) guidance of $7.25-$7.35 for the period, compared to the consensus earnings per share estimate of $7.36. The company issued revenue guidance of $57.50 billion-$58.50 billion, compared to the consensus revenue estimate of $58.10 billion.

What is Kenneth C. Frazier's approval rating as Merck & Co., Inc.'s CEO?

1,343 employees have rated Merck & Co., Inc. Chief Executive Officer Kenneth C. Frazier on Glassdoor.com. Kenneth C. Frazier has an approval rating of 94% among the company's employees. This puts Kenneth C. Frazier in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Merck & Co., Inc. own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Merck & Co., Inc. investors own include Pfizer (PFE), Johnson & Johnson (JNJ), AT&T (T), Intel (INTC), Cisco Systems (CSCO), Walt Disney (DIS), Verizon Communications (VZ), JPMorgan Chase & Co. (JPM), AbbVie (ABBV) and Home Depot (HD).

What is Merck & Co., Inc.'s stock symbol?

Merck & Co., Inc. trades on the New York Stock Exchange (NYSE) under the ticker symbol "MRK."

Who are Merck & Co., Inc.'s major shareholders?

Merck & Co., Inc.'s stock is owned by a number of institutional and retail investors. Top institutional shareholders include Northern Trust Corp (1.18%), Massachusetts Financial Services Co. MA (1.09%), FMR LLC (0.88%), Deutsche Bank AG (0.86%), California Public Employees Retirement System (0.56%) and Nordea Investment Management AB (0.47%). Insiders that own company stock include Caroline Litchfield, Frank Clyburn, Julie L Gerberding, Kenneth C Frazier, Richard R Deluca, Rita A Karachun, Robert M Davis, Sanat Chattopadhyay and Wendell P Weeks.
View institutional ownership trends
.

How do I buy shares of Merck & Co., Inc.?

Shares of MRK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Merck & Co., Inc.'s stock price today?

One share of MRK stock can currently be purchased for approximately $91.02.

How much money does Merck & Co., Inc. make?

Merck & Co., Inc. (NYSE:MRK) has a market capitalization of $230.58 billion and generates $48.70 billion in revenue each year. The company earns $13.05 billion in net income (profit) each year or $6.53 on an earnings per share basis.

How many employees does Merck & Co., Inc. have?

The company employs 68,000 workers across the globe.

When was Merck & Co., Inc. founded?

Merck & Co., Inc. was founded in 1891.

How can I contact Merck & Co., Inc.?

Merck & Co., Inc.'s mailing address is 2000 GALLOPING HILL ROAD, KENILWORTH NJ, 07033. The official website for the company is www.merck.com. The company can be reached via phone at (908) 740-4000, via email at investor_relations@merck.com, or via fax at 908-735-1253.

This page (NYSE:MRK) was last updated on 8/15/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.